Press Releases
Company News
View Summary Medivation and Astellas Provide Additional Support to Metastatic Prostate Cancer Patients Through Donations to Independent Non-Profit Patient Assistance Organization
Feb 25, 2013
PDF 11.5 KB Add to Briefcase
View Summary Medivation Announces Fourth Quarter and Year-End 2012 Financial Results Teleconference on February 28, 2013
Feb 14, 2013
PDF 9.6 KB Add to Briefcase
View Summary Enzalutamide Data Presented at ASCO GU Symposium
Feb 13, 2013
PDF 70.7 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Feb 6, 2013
PDF 8.9 KB Add to Briefcase
View Summary Medivation Elects Kathryn Falberg to Board of Directors
Feb 4, 2013
PDF 9.7 KB Add to Briefcase
View Summary Enzalutamide Data to Be Presented at ASCO GU Symposium
Jan 30, 2013
PDF 62.9 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Nov 29, 2012
PDF 9.1 KB Add to Briefcase
View Summary Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Nov 9, 2012
PDF 23.5 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Nov 7, 2012
PDF 9.2 KB Add to Briefcase
View Summary Medivation Announces Third Quarter 2012 Financial Results Teleconference on November 9, 2012
Nov 2, 2012
PDF 9.5 KB Add to Briefcase
View Summary Medivation and Astellas Announce New Data From XTANDI(R) (enzalutamide) Pivotal Study
Sep 30, 2012
PDF 64.5 KB Add to Briefcase
View Summary Medivation Effects a 2-For-1 Forward Split of Its Common Stock
Sep 24, 2012
PDF 9.2 KB Add to Briefcase
View Summary Medivation and Astellas Announce XTANDI(R) (Enzalutamide) Is Now Available for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Sep 13, 2012
PDF 63.0 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Sep 4, 2012
PDF 9.2 KB Add to Briefcase
View Summary U.S. FDA Approves XTANDI(R) (enzalutamide) After Priority Review for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Aug 31, 2012
PDF 65.5 KB Add to Briefcase
View Summary Medivation Announces a 2-for-1 Forward Split of Its Common Stock
Aug 28, 2012
PDF 9.4 KB Add to Briefcase
View Summary New England Journal of Medicine Publishes Results From Phase 3 AFFIRM Trial of Enzalutamide
Aug 15, 2012
PDF 12.0 KB Add to Briefcase
View Summary Medivation Reports Second Quarter Financial Results and Provides Corporate Update
Aug 9, 2012
PDF 23.1 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Aug 8, 2012
PDF 8.8 KB Add to Briefcase
View Summary Medivation and Astellas Announce PDUFA Action Date for Enzalutamide NDA
Aug 3, 2012
PDF 9.3 KB Add to Briefcase
Showing 41-60 of 291 Page: 1 2 3 4 5 6 7 ... 15  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Top